Icandra (Metformin Hydrochloride, Vildagliptin)

Metformin Hydrochloride reduces the amount of glucose produced by the liver and increases the sensitivity of muscle cells to insulin, thereby lowering fasting glucose. Vildagliptin blocks the enzyme DPP‑4, which prolongs the activity of natural incretin hormones, leading to increased insulin release after meals and reduced glucagon secretion. The two mechanisms complement each other to control both fasting and post‑prandial glucose.

The dosage of Icandra is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength and frequency, and patients should follow the written prescription without making any changes on their own.

Safety of Icandra in pregnancy and lactation has not been established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To request Icandra, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with the necessary import documentation.

Icandra combines metformin, a well‑established biguanide, with vildagliptin, a DPP‑4 inhibitor. Compared with metformin alone, the addition of vildagliptin offers greater post‑prandial glucose reduction and may reduce the need for extra agents. Relative to other DPP‑4 inhibitor combos, Icandra provides the metabolic benefits of metformin while maintaining a similar safety profile, making it a convenient dual‑therapy option.

Icandra tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Keep the product away from moisture, direct sunlight, and heat sources. Do not store in the bathroom or near a kitchen sink. Ensure the packaging remains sealed until use to maintain product stability.

Icandra is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing relative to meals. The tablets should be swallowed whole; they must not be crushed, chewed, or split unless specifically advised by a healthcare professional.

The most serious adverse events to monitor are lactic acidosis, which is a rare but life‑threatening metabolic condition, and severe hypoglycemia, especially when Icandra is used with other glucose‑lowering drugs. Acute pancreatitis and significant hepatic dysfunction have also been reported. Patients should seek immediate medical attention if they experience unexplained abdominal pain, rapid breathing, or signs of metabolic acidosis.

Icandra is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), significant hepatic disease, a history of lactic acidosis, or known hypersensitivity to metformin, vildagliptin, or any excipients. It should also be avoided in individuals with chronic alcohol abuse or those undergoing radiographic contrast studies unless renal function is closely monitored.